Cargando…
Calprotectin as potential novel biomarker in myasthenia gravis
Myasthenia gravis (MG) is the most common autoimmune disease affecting the neuromuscular junction by specific autoantibodies. The etiology of MG and its heterogeneity in clinical courses are poorly understood, although it was recently shown that gut microbial dysbiosis plays a critical role. Since l...
Autores principales: | Stascheit, Frauke, Hotter, Benjamin, Hoffmann, Sarah, Kohler, Siegfried, Lehnerer, Sophie, Sputtek, Andreas, Meisel, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379505/ https://www.ncbi.nlm.nih.gov/pubmed/34458711 http://dx.doi.org/10.1016/j.jtauto.2021.100111 |
Ejemplares similares
-
Serum neurofilament light chain in myasthenia gravis subgroups: An exploratory cohort and case–Control study
por: Stascheit, Frauke, et al.
Publicado: (2023) -
Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants—A Potential Novel Biomarker of Disease Activity
por: Stascheit, Frauke, et al.
Publicado: (2021) -
Burden of disease in myasthenia gravis: taking the patient’s perspective
por: Lehnerer, Sophie, et al.
Publicado: (2021) -
Correction to: Burden of disease in myasthenia gravis: taking the patient’s perspective
por: Lehnerer, Sophie, et al.
Publicado: (2022) -
Myasthenia gravis - a retrospective analysis of e-mail inquiries made to a patient organisation and specialized center to uncover unmet needs from patients and caregivers
por: Stein, Maike, et al.
Publicado: (2022)